Full Text View
Tabular View
Study Results
Related Studies
Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation
This study has been completed.
Study NCT00918346   Information provided by Santen Oy

First Received on June 9, 2009.   Last Updated on December 10, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Open-Angle Glaucoma
Ocular Hypertension
Additional conditions recognized in this trial
Glaucoma
Glaucoma, Open-Angle
Hypertension
More general conditions related to this trial
Cardiovascular Diseases
Eye Diseases
Vascular Diseases
Interventions listed in this trial
Tafluprost 0.0015%
Additional drug interventions recognized in this trial
Tetrahydrozoline
More general drug interventions related to this trial
Autonomic Agents
Cardiovascular Agents
Nasal Decongestants
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Sympathomimetics
Therapeutic Uses
Vasoconstrictor Agents
Sponsors listed in this trial
Santen Oy


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services